Will the Woodford Patient Capital Trust plc make a comeback in 2018?

There are a number of catalysts that could wake up the Woodford Patient Capital Trust plc (LSE: WPCT) performance next year.

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

It has been a lousy year for Neil Woodford’s much-talked-about Woodford Patient Capital Trust (LSE: WPCT). Thanks to a number of setbacks, shares in the trust are down by around 6.6% this year and down approximately 19% since its launch in 2015. 

The latest and most high profile setback for Neil Woodford and his team came at the beginning of November when US hedge fund Kerrisdale published a report stating that the primary revenue generating drug of the trust’s top holding, Prothena would fail, triggering a precipitous share price fall of up to 80%.  

Short attack 

Prothena accounts for around 15.6% of Woodford’s portfolio, so the trust’s performance is highly correlated to the performance of this biotech. Unfortunately, year-to-date shares in Prothena are down around 25%, and Woodford’s reputation has suffered as a result. 

Should you invest £1,000 in ITV right now?

When investing expert Mark Rogers has a stock tip, it can pay to listen. After all, the flagship Motley Fool Share Advisor newsletter he has run for nearly a decade has provided thousands of paying members with top stock recommendations from the UK and US markets. And right now, Mark thinks there are 6 standout stocks that investors should consider buying. Want to see if ITV made the list?

See the 6 stocks

However, the star fund manager continues to support the company and believes that important test results for the flagship drug NEOD001, which are set to be published next year, will help his investment case.

Woodford believes that the market is too focused on the firm’s failings, rather than its successes. Indeed, in a recent investor update the fund manager commented: “Despite a lot of positive, reassuring information across a range of the company’s late-stage and earlier-stage assets, the market appears to have focused on a delay in its Vital phase III trial for NEOD001…although short-term share price weakness can be frustrating and may feel unsettling for some investors, it cannot change the outcome for this business now.

Strength in diversification 

Even though Prothena is the Patient Capital Trust’s largest holding, it’s not the only holding. As well as this biotech, the third largest holding is online estate agent Purplebricks and only four of the top 10 holdings are publicly traded. 

Still, in many ways, trying to predict what the next year holds for the trust is a waste of time. It was founded on the idea of patient capital, in other words, long-term bets on private companies that have the potential to generate enormous returns. Neil Woodford has an excellent track record in this arena, so I believe that over the long term, his investments will product results for investors

That being said, Patent Capital might not be suitable for all investors because of its exposure to early-stage, unquoted businesses. A huge number of early-stage businesses fail, so it’s more than likely that one or more failures will hit the portfolio in the years ahead. These losses should be offset by successes in other areas over the long run, but there’s no certainty that this will be the case. 

The bottom line

So overall, Patient Capital might make a comeback in 2018, but investors shouldn’t judge this investment trust on its short-term performance. Neil Woodford has an excellent long-term track record of picking companies to invest in so he should be judged on his performance over the next 10 years, not 12 months. 

5 Shares for the Future of Energy

Investors who don’t own energy shares need to see this now.

Because Mark Rogers — The Motley Fool UK’s Director of Investing — sees 2 key reasons why energy is set to soar.

While sanctions slam Russian supplies, nations are also racing to achieve net zero emissions, he says. Mark believes 5 companies in particular are poised for spectacular profits.

Open this new report5 Shares for the Future of Energy — and discover:

  • Britain’s Energy Fort Knox, now controlling 30% of UK energy storage
  • How to potentially get paid by the weather
  • Electric Vehicles’ secret backdoor opportunity
  • One dead simple stock for the new nuclear boom

Click the button below to find out how you can get your hands on the full report now, and as a thank you for your interest, we’ll send you one of the five picks — absolutely free!

Grab your FREE Energy recommendation now

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Rupert Hargreaves has no position in any share mentioned. The Motley Fool UK has no position in any of the shares mentioned. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Tesla building with tesla logo and two teslas in front
Investing Articles

Tesla stock is down. But it may be far from out!

Tesla stock has crashed this year but its long-term record of value creation is outstanding. So, could this be a…

Read more »

A young woman sitting on a couch looking at a book in a quiet library space.
Investing Articles

£3k in savings? That’s plenty to start buying shares and earning passive income!

Christopher Ruane explores how a stock market newcomer could start buying shares with a few thousand pounds and an appetite…

Read more »

Young mixed-race couple sat on the beach looking out over the sea
Investing Articles

5 passive income techniques of stock market millionaires

Christopher Ruane details a handful of approaches many successful stock market investors use to grow their passive income streams.

Read more »

Aston Martin DBX - rear pic of trunk
Investing Articles

Down 42% in a year, here’s why Aston Martin shares could keep falling

Aston Martin shares have destroyed vast amounts of shareholder value since the company listed in 2018. Are they now a…

Read more »

One English pound placed on a graph to represent an economic down turn
Investing Articles

FTSE shares: a once in a blue moon chance to get rich?

Christopher Ruane explains why he thinks hunting for blue-chip FTSE bargains in the current market could help an investor build…

Read more »

Businessman hand stacking money coins with virtual percentage icons
Investing Articles

4 stocks Fools have bought for growth and dividends

Sometimes, an investor doesn’t have to make the choice between buying a growth stock or dividend shares! Some investments offer…

Read more »

Rolls-Royce's Pearl 10X engine series
Investing Articles

Is there no limit to how high Rolls-Royce shares might go?

Christopher Ruane sees some reasons Rolls-Royce shares could continue pushing upwards. But is he persuaded enough about the potential value…

Read more »

Businessman hand flipping wooden block cube from 2024 to 2025 on coins
Investing Articles

How much could £20k in a Stocks and Shares ISA be worth in 2030?

UK investors have enjoyed spectacular returns in their Stocks and Shares ISA's over the past five years. Would could the…

Read more »